About Dr. Srikanth M
- Dr. Srikanth M is among the top Hematologists with 27 years of experience.
- He specializes in treating lymphomas, idiopathic thrombocytopenic purpura, chronic myelogenous leukemia and metal toxicity in blood.
- After his MBBS from KMC in 1996, he completed MD in General Medicine from University College London in 2011 and did MRCP (UK) from Royal College Of Physician, London in 2000.
- He has also received a fellowship in Pathology from Royal College of Pathologists, UK and is an active member of the American Society of Hematology, Royal College of Pathologists, British Society of Hematology, European Society of Hematology, and the Royal College of Physicians.
- Dr. Srikanth has written many research papers for national and international journals.
Location
Chennai, IndiaSpecial Interest
Dr. Srikanth specializes in the following treatments-
- Ablation therapy
- Allogeneic bone marrow transplant
- Autologous bone marrow transplant
- Aplastic anemia treatment
- Bernard soulier syndrome
- Glanzmann thrombasthenia
List Of Treatments
- Aplastic Anemia
- Allogeneic Bone Marrow Transplant
- Thalassemia Treatment
- Bone Marrow Transplant
- Autologous Bone Marrow Transplant
- Sickle Cell Anemia
- Haplogenic Bone Marrow Transplant
Work Experience of Dr. Srikanth M
Dr. Srikanth M's
- MBBS, KMC
- MD, 2011, University College London, UK
- MRCP, 2000, Royal College Of Physician, London
- Diploma, The Royal College of Pathologists, UK
- Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. Blood 2010: 408
- Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma. Molecular Cancer Therapy,2009:762-770.
- Srikanth M, Davies F E, Morgan GJ. Update on novel drug combinations in Multiple Myeloma. Expert opinion on Investigational Drugs. 2008;17:1-12.
- Srikanth M, Jenner M, Wu P, Kaczmarek P, Dines S, Saso RM, Ethell M, M Potter M, Treleaven JG, Davies FE, Morgan GJ Survival and Outcome of Blastoid Variant Myeloma Following Treatment with DT-PACE. Haematologica. 2007;92:712.
- Davies FE, Srikanth M, Wu P, Jenner M, McCormack R, Cordero F, Trudel G, Morgan GJ. The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant clinical activity in relapsed/refractory myeloma patients. Blood 2007;110:2727.
- Aronson L, Davenport EL, Giuntoli SG, Srikanth M, Smith E, Morgan GJ, Davies FE.
(Get Free opinion, Quote, Medical Visa Invitation and Assistance at every step of your treatment.)